| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Innate Pharma SA (EPA: IPH)
Â
IPH Technical Analysis
5
| As on 1st Nov 2017 IPH Share Price closed @ 9.34 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.59 & Strong Sell for SHORT-TERM with Stoploss of 10.43 we also expect STOCK to react on Following IMPORTANT LEVELS. |
Â
Â
IPH Share Price
| Open | 9.40 | Change | Price | % |
| High | 9.45 | 1 Day | -0.02 | -0.21 |
| Low | 9.31 | 1 Week | 0.00 | 0.00 |
| Close | 9.34 | 1 Month | -0.80 | -7.89 |
| Volume | 130474 | 1 Year | -3.99 | -29.93 |
| 52 Week High 15.83 | 52 Week Low 9.16 | ||||
Â
EPA France Most Active Stocks
| MT | 4.53 | 12.97% |
| MT | 4.53 | 12.97% |
| GSZ | 17.56 | 3.97% |
| BRS | 12.00 | 0.00% |
| VK | 4.72 | 0.43% |
| ALALO | 0.04 | 0.00% |
| CS | 26.31 | 1.47% |
| TEC | 67.40 | 0.40% |
| ACA | 14.98 | 0.00% |
| ALAUP | 0.20 | -13.04% |
Â
EPA France Top Gainers Stocks
Â
EPA France Top Losers Stocks
Â
Â
| IPH Daily Charts |
IPH Intraday Charts |
Whats New @ Bazaartrend |
IPH Free Analysis |
|
|
Â
IPH Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 9.47 |
| RESISTANCE | 9.42 |
| SUPPORT | 9.26 |
| SUPPORT | 9.21 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
Â
IPH Target for Month July
| 4th UP TARGET | 12.26 |
| 3rd UP TARGET | 11.33 |
| 2nd UP TARGET | 10.75 |
| 1st UP TARGET | 10.17 |
| 1st DOWN TARGET | 8.53 |
| 2nd DOWN TARGET | 7.95 |
| 3rd DOWN TARGET | 7.37 |
| 4th DOWN TARGET | 6.44 |
Â
IPH Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
Â
IPH Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Â
Innate Pharma SA ( EPA France Symbol : IPH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
Â
IPH Business Profile
Innate Pharma S.A., a biopharmaceutical company, engages in the development of immunotherapy drug candidates for cancer and inflammatory diseases. The company primarily develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors (KIR) in Phase II trials for acute myeloid leukemia and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab respectively; and IPH2201/NN8765, an anti-NKG2A antibody in Phase I clinical trials for the treatment of inflammatory conditions and autoimmune diseases, and in rheumatoid arthritis. The companyÂ’s pre-clinical product candidates include IPH41, a cytotoxic mAb that targets KIR3DL2, an inhibitory receptor of NK cells; and IPH33, a blocking mAb targeting TLR3, an inducer of Type I IFN and pro-inflammatory cytokines. It has licensing agreements with Bristol-Myers Squibb for the development of IPH2102; and Novo Nordisk A/S for the development of IPH2201. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.
Â
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
